Atara Biotherapeutics (ATRA) Enterprise Value (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Enterprise Value came in at -$8.4 million in Q1 2026, up 39.6% YoY from -$6.0 million in Q1 2025, and up 1.44% on a QoQ basis from -$8.5 million in Q4 2025.
Atara Biotherapeutics (ATRA) Enterprise Value (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Enterprise Value data on file, last reported at -$8.4 million in Q1 2026.
- Quarterly Enterprise Value rose 39.6% year-over-year to -$8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.4 million (up 39.6% YoY) and the FY2025 annual result came in at -$8.5 million, up 66.31% from the prior year.
- Enterprise Value grew to -$8.4 million in Q1 2026, from -$8.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$5.7 million in Q3 2025 to a low of -$301.8 million in Q1 2022.
- A 5-year average of -$65.1 million and a median of -$46.2 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value tumbled 128.48% — and 2025, when it soared 87.68%.
- Tracing ATRA's Enterprise Value over 5 years: stood at -$242.8 million in 2022, then soared by 78.7% to -$51.7 million in 2023, then soared by 51.33% to -$25.2 million in 2024, then surged by 66.31% to -$8.5 million in 2025, then rose by 1.44% to -$8.4 million in 2026.
- The last three Enterprise Value figures came in at -$8.4 million (Q1 2026), -$8.5 million (Q4 2025), and -$5.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Atara Biotherapeutics | 140.71 Mn | 124.16 Mn | 439,000.00 | -16.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.55 Mn |
| Mar 31, 2026 | -8.36 Mn |
| Dec 31, 2025 | -8.48 Mn |
| Sep 30, 2025 | -5.74 Mn |
| Jun 30, 2025 | -22.32 Mn |
| Mar 31, 2025 | -13.84 Mn |
| Dec 31, 2024 | -25.18 Mn |
| Sep 30, 2024 | -46.60 Mn |
| Jun 30, 2024 | -35.29 Mn |
| Mar 31, 2024 | -46.24 Mn |
| Dec 31, 2023 | -51.73 Mn |
| Sep 30, 2023 | -64.94 Mn |
| Jun 30, 2023 | -46.04 Mn |
| Mar 31, 2023 | -48.89 Mn |
| Dec 31, 2022 | -242.82 Mn |
| Sep 30, 2022 | -66.46 Mn |
| Jun 30, 2022 | -72.03 Mn |
| Mar 31, 2022 | -301.81 Mn |
| Dec 31, 2021 | -106.28 Mn |
| Sep 30, 2021 | -357.25 Mn |